RNAa-Mediated Gene Activation in the Regulation of Stem Cell Fate
Lee H., Moon J., Kim SK.
Narrative Review, published in Biomolecules (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Biomolecules (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41594548
- PMCID
- PMC12839409
- DOI
- 10.3390/biom16010005
- Citations
- 1
Abstract (original English)
Stem cell fate is governed by complex transcriptional networks and dynamic chromatin architectures, with RNA molecules acting as critical regulators. Traditionally, small RNAs have been associated with gene silencing; however, growing evidence reveals that certain RNA species can also activate transcription, a phenomenon termed RNA activation (RNAa). This evolutionarily conserved mechanism functions through both synthetic small activating RNAs (saRNAs) and endogenous RNA molecules, including promoter-targeting microRNAs, small modulatory double-stranded RNAs, and circular RNAs. By modulating chromatin accessibility and engaging the transcriptional machinery, these RNAs orchestrate gene expression programs that control pluripotency maintenance and lineage-specific differentiation in stem cells. This review integrates emerging mechanistic insights and functional evidence to provide a comprehensive perspective on RNAa-mediated gene activation in stem cell biology and highlights its potential as a precise tool for controlling cell fate through epigenetic modulation.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.